GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Construction In Progress

VIVUS (STU:VIU1) Construction In Progress : €0.00 Mil (As of Mar. 2020)


View and export this data going back to . Start your Free Trial

What is VIVUS Construction In Progress?


VIVUS Construction In Progress Historical Data

The historical data trend for VIVUS's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Construction In Progress Chart

VIVUS Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

VIVUS Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

VIVUS Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


VIVUS (STU:VIU1) Business Description

Industry
Traded in Other Exchanges
N/A
Address
900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines